


Global and European Thyroid Cancer Diagnostics Market Outlook 2025–2035

Rising thyroid nodule detection, molecular testing, and screening programs to drive a 6.1% CAGR in the global diagnostics market.

ROCKVILLE PIKE, MD, UNITED STATES,
November 21, 2025 /

EINPresswire.com/ -- The [global Thyroid Cancer Diagnostics market](#) is forecasted to grow from approximately US\$2.1 billion in 2025 to US\$3.8 billion by 2035, registering a solid compound annual growth rate (CAGR) of 6.1%. This expansion is driven by increasing thyroid cancer incidence, broader adoption of screening programs, and technological advances in diagnostic methods.



A major growth catalyst is the rising rate of thyroid nodule detection, fueled by more accessible imaging tools like high-resolution ultrasound. Early detection initiatives and public awareness campaigns are further accelerating demand, especially in emerging economies where healthcare infrastructure is rapidly improving.

Papillary carcinoma — the most common form of thyroid cancer — is expected to dominate the market with an estimated 61% share in 2025. Its prevalence, along with well-established diagnostic protocols, makes it a central focus for both clinical diagnosis and research development.

In terms of diagnostic technique, imaging leads the market with a projected 42% share, thanks to its critical role in the initial evaluation of thyroid nodules. Meanwhile, biopsy methods (especially fine-needle aspiration) account for around 28%, reflecting the continued importance of cytology and molecular marker testing in confirming malignancy. Blood-based diagnostics and emerging liquid biopsy methods are also gaining traction, especially in more advanced or recurrent cancer cases.

The end-use landscape is currently dominated by hospital laboratories, capturing approximately

46% of the market. These settings benefit from integrated pathology services, multidisciplinary tumor boards, and strong institutional infrastructure. Cancer diagnostic centers are also expanding their share (around 31%) as specialized oncology facilities scale up molecular testing and precision diagnostics. Research institutes account for another significant portion, driven by biomarker discovery and clinical trial support.

To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=11766

Europe Market Dynamics

In Europe, the thyroid cancer diagnostics market is set for steady growth, underpinned by strong healthcare infrastructure, national cancer registries, and early-detection policies. The European market is expected to expand at a CAGR of 5–5.5% over the forecast period, with revenues rising from approximately US\$630 million in 2025 to more than US\$1 billion by 2035.

Countries such as Germany, France, the UK, Italy, and Spain are among the key contributors. Germany is projected to lead the European market with a substantial share, bolstered by its advanced diagnostic platforms, established endocrinology networks, and robust hospital-laboratory infrastructure. Other nations are pushing molecular diagnostics into routine care, integrating genetic testing and AI-supported imaging more aggressively.

Key Growth Drivers

Precision Medicine & Molecular Testing: As sequencing costs decline, molecular panels and mutation profiling are becoming more widely used for risk stratification and personalized treatment planning.

Technological Innovation: Advancements such as AI-driven imaging, telepathology, and liquid biopsy are transforming diagnostic workflows and expanding access.

Expanding Screening Programs: Increased screening, especially in countries with growing cancer awareness, is helping detect thyroid cancer early — boosting demand for diagnostics.

Healthcare Access in Emerging Markets: Investments in healthcare infrastructure across Asia Pacific and Latin America are increasing diagnostic coverage.

Challenges & Risks

Cost and Reimbursement: High costs of molecular tests and uneven reimbursement can delay adoption, particularly in low- and middle-income regions.

Regulatory Hurdles: Validating and obtaining approval for novel diagnostics (e.g., liquid biopsies or AI tools) remains complex.

Overdiagnosis Risk: Increased screening could lead to overdiagnosis, raising ethical and

economic questions about follow-up and treatment.

Technology Integration: Combining imaging, pathology, and molecular diagnostics into cohesive clinical workflows requires infrastructure and training.

Competitive Landscape

The market is characterized by several major global players, including Abbott, Roche, Thermo Fisher Scientific, Siemens Healthineers, BioRad Laboratories, GE Healthcare, Philips, and others. These companies are:

Developing integrated imaging + molecular diagnostic platforms

Investing in AI / digital pathology tools

Expanding into emerging markets via partnerships and distribution networks

Working to increase affordability and throughput of tests to meet broader screening demand

Strategic Implications

Diagnostic Providers should prioritize unified solutions: combining imaging, cytology, molecular markers, and AI-based risk scoring to offer end-to-end value.

Health Systems must prepare for expanding diagnostic capacity: scaling hospital labs, imaging centers, and molecular testing hubs is critical to handle rising screening demand.

Regulators and Payers should consider reimbursement pathways that support early detection and precision diagnostics — especially for high-risk populations.

Diagnostics Innovators should invest in cost-reduction strategies (low-cost sequencing, point-of-care platforms) to penetrate emerging markets.

Conclusion

The Thyroid Cancer Diagnostics market is entering a transformative phase. With projected growth to US\$13.8 billion by 2035, the industry is being reshaped by early detection programs, molecular diagnostics, and AI-enhanced imaging. In Europe, strong public health systems and rising adoption of precision tools are expected to drive consistent growth. For stakeholders — from device makers to healthcare providers — now is the moment to align on integrated, scalable, and patient-centric diagnostic strategies.

Purchase Full Report for Detailed Insights

For access to full forecasts, regional breakouts, company share analysis, and emerging trend

assessments, you can purchase the complete report
here: <https://www.factmr.com/checkout/11766>

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please
contact us – sales@factmr.com

To View Related Report :

Parathyroid Hormone Market <https://www.factmr.com/report/2582/parathyroid-hormone-market>

Cancer Tumor Profiling Market <https://www.factmr.com/report/cancer-tumor-profiling-market>

Cancer and Tumor Biomarker-based Assay Market <https://www.factmr.com/report/cancer-and-tumor-biomarker-based-assay-market>

Cancer Therapeutics Market <https://www.factmr.com/report/4296/cancer-therapeutics-market>

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

S. N. Jha

Fact.MR

+1 628-251-1583

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869157455>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.